HassaneMohamedZarourMD
Dermatology • Pittsburgh, PAProfessor, Medicine and Dermatology, University of Pittsburgh School of Medicine
Dr. Zarour is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5117 Centre Ave
Research Pavilion, Suite 1.32a
Pittsburgh, PA 15213Phone+1 412-623-3272
Education & Training
University of the Mediterranean Faculty of MedicineClass of 1991, Dermatology and Cutaneous Oncology
Certifications & Licensure
PA State Medical License 2003 - 2024
Clinical Trials
- CpG 7909/Montanide ISA 720 With or Without Cyclophosphamide in Combination Either With NY-ESO-1-derived Peptides or the NY-ESO-1 Protein for NY-ESO-1-expressing Tumors Start of enrollment: 2009 Jan 01
- NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma Start of enrollment: 2014 Jan 24
- Treatment of Advanced Melanoma With MK-3475 and Peginterferon Start of enrollment: 2014 Jul 24
Publications & Presentations
PubMed
- 995 citationsUpregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+ T cell dysfunction in melanoma patientsJulien Fourcade, Zhaojun Sun, Mourad Benallaoua, Philippe Guillaume, Immanuel F. Luescher
The Journal of Experimental Medicine. 2010-09-27 - 408 citationsTIGIT in cancer immunotherapy.Joe-Marc Chauvin, Hassane M. Zarour
Journal for Immunotherapy of Cancer. 2020-09-01 - 455 citationsProgrammed Death-Ligand 1 Expression and Response to the Anti–Programmed Death 1 Antibody Pembrolizumab in MelanomaAdil Daud, Jedd D. Wolchok, Caroline Robert, Wen-Jen Hwu, Jeffrey S. Weber
Journal of Clinical Oncology. 2016-10-31
Press Mentions
Combination Therapy Shows Promising Results in Treating Stage 3 MelanomaOctober 31st, 2024- Fecal Microbiota Transplants May Improve Resistance to Melanoma ImmunotherapyOctober 13th, 2021
- Fecal Microbiota Transplant Changes Melanoma Immunotherapy Non-Responders to RespondersFebruary 5th, 2021
- Join now to see all
Grant Support
- Reversing Melanoma-Induced T Cell DysfunctionNational Cancer Institute2011–2012
- Optimization Of Melanoma Vaccines With T-Helper EpitopesNational Cancer Institute2009–2012
- Melanoma Vaccines With Peptides, Protein And AdjuvantNational Cancer Institute2005–2009
- Optimization Of Melanoma Vaccine With T Helper EpitopeNational Cancer Institute2002–2007
- Promune W/Wo Chemo Trtmt Stage III B/C/Iv MelanomaNational Center For Research Resources2005
- Pilot Immun W/Cpg 7909 Or Multi-Epitope Immunogen Nyeso-1National Center For Research Resources2005
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
